BC
DFTX

Belmont Capital’s Definium Therapeutics DFTX Stock Holding History

Belmont Capital’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$39 Hold
6
– – ﹤0.01% 167
2025
Q1 		$35 Hold
6
– – ﹤0.01% 170
2024
Q4 		$42 Hold
6
– – ﹤0.01% 120
2024
Q3 		$34 Hold
6
– – ﹤0.01% 168
2024
Q2 		$43 Hold
6
– – ﹤0.01% 199
2024
Q1 		$56 Hold
6
– – ﹤0.01% 186
2023
Q4 		$22 Hold
6
– – ﹤0.01% 167
2023
Q3 		$19 Hold
6
– – ﹤0.01% 169
2023
Q2 		$21 Hold
6
– – ﹤0.01% 176
2023
Q1 		$19 Hold
6
– – ﹤0.01% 130
2022
Q4 		$0 Buy
+6
New +$17 ﹤0.01% 131
2022
Q1 		– Sell
-7
Closed – – 76
2021
Q4 		$0 Hold
7
– – ﹤0.01% 77
2021
Q3 		$0 Buy
+7
New +$303 ﹤0.01% 77

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Belmont Capital's DFTX Position: Q2 2025 in Review

Belmont Capital held its Definium Therapeutics (DFTX) position steady in Q2 2025 at 6 shares worth $39. The position accounts for ﹤0.01% of the portfolio, ranked #167.

Belmont Capital first reported a position in DFTX in Q3 2021 and has held it in 13 quarters since. The position peaked at $56 in Q1 2024. 181 funds tracked by Wall St. Rank hold DFTX as of Q2 2025.

  • Belmont Capital held 6 shares of Definium Therapeutics worth $39 as of Q2 2025.
  • Belmont Capital left its Definium Therapeutics share count unchanged in Q2 2025.
  • Definium Therapeutics made up ﹤0.01% of Belmont Capital's portfolio in Q2 2025, its #167 holding.
  • Belmont Capital first reported a position in Definium Therapeutics in Q3 2021 and has held it in 13 quarters since.
  • Belmont Capital's Definium Therapeutics position peaked at $56 in Q1 2024.
  • 181 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2025.

Based on Belmont Capital's 13F filing for Q2 2025, filed 12 Aug 2025.